3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
1
Interventions
Cetuximab
5
Bevacizumab
4
pembrolizumab
3
Leucovorin
3
Irinotecan
3
Fluorouracil
3
trifluridine tipiracil drug combination
2
trastuzumab deruxtecan
2
larotrectinib
2
encorafenib
2
binimetinib
2
Trastuzumab
2
Oxaliplatin
2
Nivolumab
2
HMPL-013
2
Afatinib
2
ulixertinib
1
tucatinib
1
trastuzumab biosimilar HLX02
1
trametinib
1
sotorasib
1
sapanisertib
1
relatlimab
1
regorafenib
1
pralsetinib
1
pertuzumab
1
palbociclib
1
osimertinib
1
omipalisib
1
ipatasertib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
Colorectal Neoplasms
×
regorafenib
×
Clear all
NCT05198934
2026-04-27
CodeBreak300
Amgen
Phase 3
Completed
160 enrolled
1 FDA